Benzinga | Nov 16, 2020 11:30AM EST

Canaccord Genuity Maintains Buy on Biohaven Pharmaceutical, Raises Price Target to $110

Canaccord Genuity maintains Biohaven Pharmaceutical (NYSE:BHVN) with a Buy and raises the price target from $80 to $110.